Skip to main content

Page last checked

Selective amylin receptor agonist peptide (investigational) · safety

Eloralintide side effects

Also called LY3841136.

The eloralintide side effects reported most often are nausea, fatigue and vomiting. The full list is below, with the cited trial report cited at the bottom of the page.

Eloralintide is an experimental weekly shot for weight loss. It works on amylin receptors, not GLP-1. Researchers are studying Eloralintide for weight loss.

A Phase 2 trial reported average weight loss across six study groups. A larger Phase 3 trial is recruiting, so there is no approved dose or launch date.

Further down: the full list with frequencies · when to get medical help · questions

Medically reviewed by Kenneth Montecillo, MD2026-09-07open the primary sources

At a glance

Common reactions listed

3

Serious reactions listed

0

Boxed warning

No label exists

Strongest source

Human trial

The counts show how many distinct reactions the cited trial report names. The percentages show how often a reaction appeared in a study group, not the chance that it will happen to you.

Common reactions

The full list, as reported across the available trial evidence. There is no approved label to read frequency bands off, so these are the trials’ own figures. Where the source gives only a band, the table keeps that band instead of turning it into an exact rate.

◆ Common reactionstrial-reported
ReactionFrequency
NauseaPhase 2 Eloralintide groups: 11% to 64%, versus 13% with placebo
FatiguePhase 2 Eloralintide groups: 0% to 46%, versus 11% with placebo
VomitingPhase 2 Eloralintide groups: 0% to 25%, versus 0% with placebo

Human trialEvery reaction above comes from a cited trial. These are study findings, not instructions on what to take.

When to seek medical care

The trial report does not give a separate list of serious reactions. There is also no approved label. That gap does not mean serious reactions cannot happen. This compound has been studied in fewer people and for less time than an approved drug.

EmergencySome symptoms should not wait for an appointment. Call emergency services (911 in the US) if they are severe, getting worse fast, or involve trouble breathing, chest pain, fainting or confusion.

2Read deeperTiming, evidence limits, and product context

What the 48-week trial can—and cannot—show

The page above comes from a dose-finding study with 263 people. It tested weekly doses of 1 mg · 3 mg · 6 mg · 9 mg · 9 mg · 9 mg. The study shows what happened during that window. It may miss rare or later problems.

This page preserves 3 common reactions and 0 serious entries from that report. A missing reaction is outside this bounded record; it is not a result that the reaction cannot occur.

  • Investigational compound — no approved dose or prescribing label exists
  • Side-effect rates varied widely across the six Phase 2 study groups
  • The recruiting Phase 3 trial has no results or approved launch date

Eloralintide is investigational.

It has no prescribing label or approved dose. The amounts below belong to monitored study groups and are not a schedule for personal use. A recruiting Phase 3 study has no results yet.

Making side effects easier to discuss

None of this is a recommendation, and none of it is treatment. These are the side-effect topics clinicians and drug labels tend to raise. They are written down here so your conversation with a prescriber starts further along than it otherwise would.

Meal size and pace
Portion size and how fast you eat are usually the first things raised when nausea tracks with meals. They come up because they are things you can describe precisely at your next appointment, which makes them useful information either way.
Fluids
Fluid intake comes up in almost every side-effect conversation. The reason is already on this page: where kidney injury appears in the serious list, dehydration is the route named. Vomiting and diarrhea are what lose fluid. That is why clinicians want to hear about them early rather than have you put up with them quietly.
Noticing patterns rather than guessing
Clinicians often suggest keeping track of what came before a bad day — the meal, the timing relative to the injection, how recently the dose changed. A specific account is worth more at an appointment than a vague one, and it is the part only the person taking the compound can supply.
How fast the dose moves
How quickly the dose goes up is a clinician’s call and belongs in that conversation, not on this page. Approved schedules set a minimum time at each step and treat the next step as conditional on the current one going well. Staying longer at a step is a recognized option, and the prescriber is the one who uses it.
Constipation as its own topic
Constipation usually gets discussed separately from nausea, because what helps is different and because anything reached for over the counter interacts with the rest of a medicine list. That makes it a question for a clinician or pharmacist rather than a search box.
Reporting rather than enduring
A side effect is information, not a test you failed. Clinicians want to hear about reactions early. They can hold a step, change the timing or look for another cause. The right choice depends on your symptoms, history and other medicines.

Starting, holding, changing, pausing or stopping a dose is a decision for the person who prescribes it.

Common questions

How long do eloralintide side effects last, and do they go away?

The 48-week trial report does not establish a set number of days for any reaction. It records whether an event occurred during the study, not a reliable personal countdown for when it will stop.

What are the most common eloralintide side effects?

Nausea, fatigue and vomiting — the table above has the rest, each with its frequency band and source.

Does eloralintide have a boxed warning?

No, because a boxed warning is part of an FDA-approved label and eloralintide has no approved label. That reflects what regulatory review has and has not covered, not a finding that serious risks were looked for and ruled out.

Can the eloralintide dose be lowered if side effects are hard to tolerate?

That decision belongs to the prescribing clinician. No approved schedule exists for this compound, so there is no labeled framework for adjusting a dose. That leaves the prescriber as the only place the decision can sit.

Were hair loss, fatigue or constipation listed for eloralintide?

In the 48-week report, fatigue was listed; hair loss and constipation were not. That is a statement about the paper’s recorded terms, not proof that an unlisted symptom cannot occur.

What should someone do about a serious eloralintide reaction?

Contact a clinician promptly, and emergency services if symptoms are severe or getting worse quickly. The available sources do not list any reactions as separately serious. That means there is no early-warning list here—not that serious reactions are impossible.

Do the frequencies on this page mean the chance it happens to one person?

No. These figures describe groups in a study. A band shows how often a reaction appeared under that trial’s conditions. It cannot predict what will happen to one person.

Related

The schedule these reactions were recorded against, the comparisons, and the sourcing rules behind every grade on this page.

What eloralintide is, how it is used, and what has been studied

Eloralintide is a selective amylin receptor agonist peptide (investigational).

What a studied eloralintide figure is, and what it is not

Arm by arm from 48-week Phase 2 weight-management trial, with the placebo comparison where the paper reports one.

Every calculator on this site, eloralintide and the rest

Every intermediate value is printed, for eloralintide or any other vial.

Fatigue weighed class-wide, including eloralintide

Named fatigue entries, grouped figures and absences kept distinct, apart from eloralintide.

Nausea weighed class-wide, including eloralintide

Named nausea entries, grouped figures and absences kept distinct, apart from eloralintide.

The proceedings behind the eloralintide note on this page

Newest entry first, with eloralintide among them.

Every compound guide, eloralintide and the rest

Class, approval status and strongest available source for every compound, with eloralintide as one example

What a source must satisfy to appear on eloralintide

Every figure ties to a primary source, or it does not ship, including Eloralintide

1primary source, each with the day we read it — open the documents used on this page